Background: The results of multiple implantable cardioverter-defibrillator (ICD) studies have demonstrated a survival benefit in specific high-risk populations, leading to the expansion of ICD implantation rates worldwide. Because the ICD reduces the incidence of sudden cardiac death, patients with these devices more often die of non-arrhythmic causes. For those with a malignancy, little is known about their preferences for disabling ICD therapy.
Methods: The objective of the present study was to evaluate whether patients with an ICD and a malignant tumor desire deactivation of their ICD in order to have a death without ICD interventions, which are life-prolonging, bothersome, and prevent a peaceful death. All deceased patients having had an ICD implanted at our institution were retrospectively analyzed with respect to whether the option of disabling ICD therapy had been discussed and whether the ICD had been deactivated.
Results: Two hundred and seventy-two patients received an ICD at our institution between January 1, 1994, and January 31, 2007. Thirty-six of the patients have died, and of these eight had a malignant tumor. In six of these eight patients (75%) the option of disabling their ICD therapy was discussed extensively; none wished to abandon the possibility of terminating a malignant arrhythmia by the ICD.
Conclusions: With the use of ICDs, patients with heart failure are more frequently protected from arrhythmic death, and consequently treating physicians are increasingly confronted with ICD patients presenting with a malignant tumor or other noncardiac terminal disease. In these situations, dialogue between the treating physician and the patient about the possibility of withdrawing ICD therapy is important to terminal care. The physician must be aware that the patient's attitude may contrast with his/her own, and that the patient may be resolute in maintaining ICD protection from arrhythmic death.